SKIN CANCER. Most common cancer diagnosis 40% of all cancers
|
|
- Caren Rich
- 5 years ago
- Views:
Transcription
1 SKIN CANCER Most common cancer diagnosis 40% of all cancers
2 OBJECTIVES Review common and uncommon cancers of the skin. Special emphasis on melanoma and dysplastic nevus Review pathology/tnm/staging, which is critical in underwriting Review survival/mortality studies, although some are limited
3 GENERAL POINTS Careful reading of pathology report Grade & stage critical for solid tumors Margins of resection, mitoses, necrosis, vascular invasion Beware of under-staging. Clin. vs. path. Is treatment optimal? Clinical, laboratory, pathology evidence of recurrence If pathology report is inadequate or unavailable, try doctor records
4 PRIMARY TYPES Basal Cell Carcinoma 80%(800,000/yr) SquamousCell Carcinoma 16% Malignant Melanoma (Largely related to sun exposure) 4%
5 SKIN CANCER Non-melanoma most common cancer world-wide, incidence increasing Biggest risk factors SUN, genetics, tobacco use in that order Recent increase in those < 40, esp. basal cell cancer in young females Christenson. JAMA 2005; 294:
6 BASAL CELL CARCINOMA Low metastatic potential (met. rate <0.1%) Mortality rate 0.05% (deep invasion >10 cm.). Rarely fatal. Cure highly probable. Face, head Basosquamous cell carcinoma greater risk. Treat as squamous cell cancer. Tx Moh s surgery, radiation, cryosurgery, topical (5FU), electrosurgery -90 % cure Second BCC common (40% in 5 yrs)
7 SQUAMOUS CELL CARCINOMA Most remain localized & curable Precursor actinic, solar, senile keratosis Lifetime SCC risk: 6-10% if multiple lesions Seborrheic keratosis not a precursor Assoc. w/ sun, smoking, tx w/ PUVA or immune suppression If one SCC high chance of 2 nd SCC (or BCC or melanoma) within 5 yrs
8 SQUAMOUS CELL CARCINOMA Bowen s Disease SCC in situ Up to 2 cm tumors- few recur or metast. Recurrence rate 8-16% - depends on size, depth, facial areas, differentiation, tx Mets w/ SCC 1-5% (85% of those in LN). > risk if face, scalp, ears, scars, burns, if d/t radiation/immune suppression, older men
9 TMN FOR SCC OF SKIN Tis Carcinoma in situ (non-invasive) T1 - < 2 cm diam. < 2 high risk features T2 - >2 cm or any T w/ > 2 high risks T3 & T4 (much deeper invasion) maxilla, mandible, orbit, etc.
10 SCC HIGH RISK FEATURES Depth > 2 mm or Clark level IV or perineural invasion Location ear or hair-bearing lip Poorly differentiated or undifferentiated (does not look like normal skin)
11 SKIN SCC STAGE Stage 0 Stage I Stage II Stage Stage Tis T1 T2 III - T3 III T1 N0 M0 N0 M0 N0 M0 N0 M0 N1 M0
12 SCC TREATMENT Moh s micrographic surgery Other surgery 97% cure 92% cure Other tx less effective: radiation, cryotherapy, 5FU Surgery for recurrence 77% cure Need close follow-up after treatment
13 SCC MORTALITY Overall mortality 1% (1000/yr) Pos lymph nodes 25-35% 5 yr. survival & < 20% 10 yr. survival Distant mets - < 10% 5 yr. survival 5 year cure rate > 90%
14 MALIGNANT MELANOMA 75% of T1 melanomas are T1a w/ 95% five yr survival & 93% ten yr survival Thickness proportional to how long it has been there & to risk Thickness & ulceration: best predictors of survival More common if freckles, moles (esp. atypical), nonmelanoma skin ca and sporadic sun exposure
15 MALIGNANT MELANOMA 50% of melanoma - no preexisting lesion 10% - familial If family history, 8-12 fold increased incidence If family history, need exam Q 6 months 2/3 secondary to sunlight (UVA & UVB) -Intense sunburn in childhood 4-5 x Sporadic sun exposure (cf. SCC, when sun more constant exposure)
16 MALIGNANT MELANOMA Life time risk 1 in 37 or 50 (1/600 in 1965) Rare until age 10 Recent increases ages & up Mortality ratio stable or mild increase except men > 65 (up 150%) With early dx, overall survival 90%
17 ABCDE MELANOMA DX A asymmetry B border irregularity C color variegation D diameter >6 mm. (pencil eraser) E evolving (change, itching, bleeding) Rigel. CA 2010;60:
18 MELANOMA TYPES Superficial spreading radial growth- 70% Nodular vertical invasion % Acral dark skin, soles, palms, nails- 5% Lentigo elderly, in situ for years- 5% Abbasi. JAMA 2004;292:
19 MALIGNANT MELANOMA Early radial (horizontal) growth, thin & confined to epidermis In situ or microinvasion almost all curable But risk of another melanoma Vertical growth phase into dermis metastatic potential
20 MELANOMA PATH REPORT In situ or invasive Breslow thickness & Clark level Ulceration + or Mitoses many or very few Growth - radial or vertical Regression Margins of resection Satellites or vascular invasion
21 MM 10 YEAR SURVIVAL Extremity <0.76 mm, women <60: 99% Extremity <0.76 mm, men < 60: 98% Axis <0.76 mm, women < 60: 97% Axis < 0.76mm, men < 60: 94% Extremity < 0.76 mm, women >60: 98% Extremity < 0.76 mm, men >60: 96% * Axis: trunk, head, neck, volar, subungual
22 MM 10 YEAR SURVIVAL Axis <0.76 mm, women >60: 92% Axis <0.76 mm, men > 60: 84% Extremity mm, women <60: 96% Extremity mm, men <60: 93% Axis mm, women <60: 86% Axis mm, men <60: 75% Extremity mm, women >60: 90% Extremity mm, men > 60: 81%
23 MM-10 YEAR SURVIVAL Axis mm, women >60: 67% Axis mm, men >60: 50% Extremity mm, women <60: 89% Extremity mm, men <60: 80% Axis mm, women <60: 65% Axis mm, men<60: 48% Extremity mm, women >60: 73% Extremity mm, men >60: 57% Ann Int Med 1996;125:369
24 MELANOMA 2002 AJCC STAGING Tis melanoma in situ T1a- < or = 1.0 mm. w/o ulceration, level II,III T1b -< or =1.0 mm. w/ ulceration or level IV, V T2a mm. w/o ulceration T2b mm. w/ ulceration T3a mm. w/o ulceration T3b /0 mm. w/ ulceration H/O Melanoma, risk of 2 nd is x. Recent study: 8% risk of 2 nd melanoma w/in 2 yrs.
25 TNM & STAGING Stage 0 Tis (jn situ) Stage IA T1a (N0 M0 for all I & II) Stage IB T1b or T2a Stage IIA T2b or T3a Stage IIB T3b or T4a Stage II C T4b Stage IIIa T1-4a, N1a or N2a
26 MELANOMA TNM/STAGING Stage I low risk for metastases and melanoma mortality Stage II intermediate risk for metastases & melanoma mortality Balch. CA 2004; 54:
27 MM STAGE/ 5 YR SURVIVAL IA (T1a nonulcerated) - 95% IB (T1b ulcerated) 91% IB (T2a nonulcerated) 89% IIA (T3a nonulcerated) 79% IIA (T2b ulcerated) 77% IIB (T4a nonulcerated) 67% IIB (T3b ulcerated) 63% Balch. CA 2004; 54:
28 MM - STAGE/10 YR SURVIVAL IA (T1a nonulcerated) 93% IB (T1b ulcerated) 82% IB (T2a nonulcerated) 80% IIA (T2b ulcerated) 68% IIA (T3a nonulcerated) 68% IIB (T3b ulcerated) 53% IIB (T4a nonulcerated) 55%
29 MM STAGE/ MORTALITY RATIO Stage IA Slightly > 100% MR Stage IB 250% MR Stage IIA 400% MR Stage IIB 600% MR Stage IIC 900% MR Stage IIIA 1200% MR REMEMBER LONG MORTALITY TAIL IN - long risk for underwriting
30 HISTORY OF MELANOMA 100 fold increase risk if previous melanoma in patient 200 fold increase risk if 2 family members with melanoma 1200 fold increase risk if both personal and family history of melanoma Naeyaert. NEJM 2003;349:
31 T1 & T2 MELANOMAS T1a - < 1.0 mm, no ulceration, only level II and level III (Clark) T1b - < 1.0 mm but level IV or V or ulceration regardless of level Clark level important only thin melanoma Ulceration raises lesion to next stage (IB is either T1b or T2a) Stage I & II no evidence of mets
32 MALIGNANT MELANOMA Path stage (pt) more information than clinical stage (ct) Caution: amelanotic melanoma (colorless) usually nodular; often overlooked Melanoma in situ. No invasion, 100% survival, but still risk of additional melanomas
33 MELANOMA TREATMENT Complete excision w/ adequate margins of surrounding tissue for cure (all directions) AVOID shave biopsies. Need subq for depth. May transect melanoma Sentinel node bx in melanomas 1.2mm to 3.5 mm. (T2-3) survival higher cf no bx Morton. NEJM 2006;355: If sentinel node +, then complete node dissection w/ adjuvant tx for hope of cure
34 MELANOMA METS If + lymph node on bx, then have better survival than only clinical dx (by 20-29%) Satellite mets in skin by primary MM has equally poor prognosis as + lymph nodes (N2 & stage III) Stage III ten yr survival 9-63%
35 MALIGNANT MELANOMA Ulceration, bleeding, regression, satellites, high mitotic rate: all worse prognosis. Pos. lymph nodes worst prognosis Dermoscopy (surface microscopy) now allows differentiation of benign and malignant pigmented lesions P.S. can also have melanoma in eye or GI tract (increase risk if dysplastic nevus)
36 MELANOMA - FUTURE Identification of gene alterations will be basis of future classification of melanoma & provide rationale for drug treatment & effective targeted therapy Advance/Laboratory, Feb. 2011, p. 26 For other new techniques being investigated -Rigel CA 2010; 60:
37 DYSPLASTIC NEVI AKA atypical mole, BK mole, Clark s nevi Path & clin. between nevus and melanoma No consensus on formal definition Precursor or marker for melanoma Appears at puberty. Prevalent < y/o Often 50 - >100 nevi on body Autosomal dominant inheritance but not always family history
38 DYSPLASTIC NEVUS Occurs in 2-18% of white adults (20% of all have at least one atypical mole) Median age 33 Occurs in 17-59% of melanoma patients Most common on trunk, esp back Dysplastic nevus syndrome: >100 moles, with one > 8mm and one atypical mole May evolve from nevus or de novo
39 DYSPLASTIC NEVUS Relationship of familial melanoma & dysplastic nevus is FAMMM familial atypical multiple mole- melanoma syndrome. AKA dysplastic mole syn. >15 x relative risk of melanoma if multiple Intense f/u q 6-12 months w/ photos Also increased incidence others cancers Naeyaert. NEJM 2003;349:
40 KINDREDS & DYSPLASTIC NEVUS SYNDROME A: sporadic atyp mole 1 in family B familial atyp mole 2 or more in family C sporadic atyp mole & melanoma 1 in family w/ both conditions D1 familial atyp mole & melanoma 2 or more w/ atyp mole; 1 in family w/ both D2 familial atyp mole & MM 2 or more with both atyp mole & MM
41 DYSPLASTIC NEVUS TREATMENT Most do not evolve into melanoma Most are therefore not excised unless changes occur Stress again need for close follow-up, including photos, for both dysplastic nevus and melanoma patients
42 LESS COMMON SKIN TUMORS Keratoacanthoma looks like SCC but rapid growth. Most regress to scar. A few may be or become malignant w/ mets Sebaceous carcinoma. Malignant, 10 to 30 % mortality in 5 years. Face & head, esp. eyelids. Assoc. w/ 2 nd cancer
43 LESS COMMON SKIN TUMORS Merkel cell carcinoma. Rare, aggressive, esp. older males or immunocompromised. Tend to recur or metastasize. Rapid growth, esp. face. Assoc. w/ 2 nd cancers. Dermatofibrosarcoma protruberans. Locally invasive, similar to basal cell ca.
44 CUTANEOUS LYMPHOMA 90% T cell lymphoma. Majority are mycosis fungoides Next, anaplastic large T cell lymphoma 10% B cell lymphoma 20-25% are stage IA, w/ good survival 2% of all lymphomas are cutaneous
45 CUTANEOUS LYMPHOMA Diagnosis by biopsy only No consensus: dx of mycosis fungoides For all immunophenotyping to diagnose abnormal lymphocyte clones Can ultimately involve lymph nodes, blood and visceral organs More aggressive leukemic variant - Sezary
46 TNM CUTANEOUS LYMPHOMAS T0 suspicious lesions T1 limited lesions < 10% skin surface T2 generalized lesions, > 10% skin T3 skin tumors
47 TNM STAGE MYCOSIS FUNGOIDES Stage IA T1 N0 (<10%): 20-25% have Stage IB T2 N0 (>10%): 30-40% have Stage IIA T1-2, N1
48 SURVIVAL MYCOSIS FUNGOIDES Stage IA studies show excellent prognosis and long-term survival Stage IB & IIA 20% die of MF. Median overall survival > 11 years. Higher stages (IIB, III and up) very short survival
49 PRIMARY CUTANEOUS ANAPLASTC LARGE T CELL 8-18% of primary cutaneous lymphomas Radiation therapy for most Some regress spontaneously Some studies good survival
50 SUMMARY Many common skin tumors have excellent survival if adequate treatment Melanoma may have excellent survival if diagnosed early and if treated adequately Rarer skin tumors require caution T1, esp. T1a, and Stage I cancers have the best prognoses, best UW risks All skin tumors require close follow-up
51 Thank you for the privilege of presenting this topic Jack Swanson, M. D.
Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1
Skin Cancer AMERICAN OSTEOPATHIC COLLEGE OF OCCUPATIONAL & PREVENTIVE MEDICINE OMED 2012 October 8, 2012 E. Robert Wanat II, D.O., M.P.H. Learning Objectives: Identify the 3 Basic Types of Skin Cancer
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationClinical characteristics
Skin Cancer Fernando Vega, MD Seattle Healing Arts Clinical characteristics Precancerous lesions Common skin cancers ACTINIC KERATOSIS Precancerous skin lesions Actinic keratoses Dysplastic melanocytic
More informationCutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.
Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma
More informationIdentifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018
Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma
More informationIT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY
IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY Skin, Bones, and other Private Parts Symposium Dermatology Lectures by Debra Shelby, PhD, DNP, FNP-BC, FADNP, FAANP Debra Shelby,
More informationBenign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc
1 Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc Benign lesions Seborrheic Keratoses: Warty, stuck-on Genetics and birthdays Can start in late
More informationToby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma
Distinguishing Pigmented Skin Lesions and Melanoma Toby Maurer, MD University of California, San Francisco Epidemiology of Melanoma Lifetime risk of an American developing melanoma 1935: 1 in 1500 1980:
More informationToby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma
Distinguishing Pigmented Skin Lesions and Melanoma Toby Maurer, MD University of California, San Francisco Epidemiology of Melanoma Lifetime risk of an American developing melanoma 1935: 1 in 1500 1980:
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationLearning Objectives. Tanning. The Skin. Classic Features. Sun Reactive Skin Type Classification. Skin Cancers: Preventing, Screening and Treating
Learning Objectives Skin Cancers: Preventing, Screening and Treating Robert A. Baldor, MD, FAAFP Professor, Family Medicine & Community Health University of Massachusetts Medical School Distinguish the
More informationDermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial
Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial Cutaneous Oncology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI
More informationSkin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012
Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012 Case Presentation 57 yo man with 3 month hx of a nonhealing < 1 cm right
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Assistant Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationLiving Beyond Cancer Skin Cancer Detection and Prevention
Living Beyond Cancer Skin Cancer Detection and Prevention Cutaneous Skin Cancers Identification Diagnosis Treatment options Prevention What is the most common cancer in people? What is the most common
More informationMalignant Melanoma Early Stage. A guide for patients
This melanoma patient brochure is designed to help educate melanoma patients and their caregivers. It was developed under the guidance of Dr. Michael Smylie, Professor, Department of Oncology, University
More informationPeriocular Malignancies
Periocular Malignancies Andrew Gurwood, O.D., F.A.A.O., Dipl. Marc Myers, O.D., F.A.A.O. Drs. Myers and Gurwood have no financial interests to disclose. Course Description Discussion of the most common
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationDermatological Manifestations in the Elderly. Sanjay Siddha Staff Dermatologist UHN & MSH
Dermatological Manifestations in the Elderly Sanjay Siddha Staff Dermatologist UHN & MSH Disclosure No actual or potential conflicts of interest or commercial relationships to declare Objectives Recognize
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Melanoma 2013 2014 NAACCR Webinar Series April 3, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationMelanoma: The Basics. What is a melanocyte?
Melanoma: The Basics What is a melanocyte? A melanocyte is a normal cell, found in the skin, which produces melanin. Melanin is a black or dark brown pigment that is seen in the skin, hair, and parts of
More informationGlenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine
Glenn D. Goldman, MD University of Vermont Medical Center University of Vermont College of Medicine Recognize and identify the main types of skin cancer and their precursors Identify and understand new
More informationLarge majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest risk.
Basics of Skin Cancer Detection and Treatment of Non- Melanoma Skin Cancers Large majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest
More information1. Opdivo + Ipilumimab is now the first line therapy for metastatic melanoma.
Melanoma UpToDate: Introduction: Risk Factors: 1. Opdivo + Ipilumimab is now the first line therapy for metastatic melanoma. Median age = 50 yrs Incidence is rising - Sun exposure: UVB (290-320nm) > UVA
More informationVACAVILLE DERMATOLOGY
Connecting the Dots on those Spots NANDAN V. KAMATH, M.D. VACAVILLE DERMATOLOGY Sources All of the photos were taken with permission from the Dermnet NZ website - Dermnet New Zealand after communicating
More informationAn Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center
An Overview of Melanoma Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center Melanoma Statistics Median age at presentation 45-55 55 years Incidence: 2003 54,200 cases
More informationTechnicians & Nurses Program
ASCRS ASOA Symposium & Congress Technicians & Nurses Program May 6-10, 2016 New Orleans Evaluation and Treatment of Eyelid Malignancies Richard C. Allen MD PhD FACS Professor Section of Ophthalmology Dept.
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More information1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.
Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.
More informationUpdates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD
Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do
More informationSpringer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone
Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published
More informationDesmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC
R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o
More informationGlenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine
Glenn D. Goldman, MD Fletcher Allen Health Care University of Vermont College of Medicine Recognize and identify the main types of skin cancer Understand how and why Mohs surgery is utilized for the treatment
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationPathology of the skin. 2nd Department of Pathology, Semmelweis University
Pathology of the skin 2nd Department of Pathology, Semmelweis University Histology of the skin Epidermis: Stratum corneum Stratum granulosum Stratum spinosum Stratum basale Dermis: papillary and reticular
More informationLUMPS AND BUMPS: AN ORGANIZED APPROACH TO DIAGNOSIS AND MANAGEMENT
LUMPS AND BUMPS: AN ORGANIZED APPROACH TO DIAGNOSIS AND MANAGEMENT Tammy P. Than, M.S., O.D., F.A.A.O. The University of Alabama at Birmingham / School of Optometry 1716 University Blvd. Birmingham, AL
More informationIdentifying Benign and Malignant Skin Lesions. No Disclosures. Common Benign Lesions. Benign Lesions 2/25/2018. Stucco Keratoses.
Dermatology in Primary Care Identifying Benign and Malignant Skin Lesions Christy Quire Baker, APRN, FNP-BC, DCNP Dermatology Certified Nurse Practitioner No Disclosures Common Benign Lesions Seborrheic
More informationCommon Benign Lesions and Skin Cancers. 22nd May 2015 Dr Mark Foley
Common Benign Lesions and Skin Cancers 22nd May 2015 Dr Mark Foley Thank you for downloading this file. This intended to supplement the presentation given at the NZ Wound Care Conference, it is not intended
More informationMelanoma. Lynn Schuchter, M.D. Associate Professor of Medicine Abramson Cancer Center of the University of Pennsylvania
Melanoma Lynn Schuchter, M.D. Associate Professor of Medicine Abramson Cancer Center of the University of Pennsylvania WHAT IS MELANOMA? Melanoma is a type of skin cancer (a serious skin cancer because
More informationSkin Cancer 101: Diagnosis and Management of the Most Common Cancer
Skin Cancer 101: Diagnosis and Management of the Most Common Cancer Sarah Patton, PA-C, MSHS Skin Surgery Center www.skinsurgerycenter.com Seattle/Bellevue, WA Skin cancer Skin cancer is by far the most
More informationPage 1 of 15 Title Authored By Course No Contact Hours 2 Skin Cancer the Real Picture for Early Detection and Treatment Cheryl Sommer RN, MSN, ARNP SC120604 Purpose The purpose of this course is to provide
More informationSubject Index. Dry desquamation, see Skin reactions, radiotherapy
Subject Index Actinic keratosis disseminated disease 42 surgical excision 42 AIDS, see Kaposi s sarcoma Amifostine, skin reaction prophylaxis 111 Basal cell carcinoma, superficial X-ray therapy Bowen s
More informationSkin Malignancies. Presented by Dr. Douglas Paauw
Skin Malignancies Presented by Dr. Douglas Paauw Disclosure: Dr. Paauw has no significant financial interest in any of the products or manufacturers mentioned. How Common Is Skin Cancer? *½ of all White
More informationDermoscopy: Recognizing Top Five Common In- Office Diagnoses
Dermoscopy: Recognizing Top Five Common In- Office Diagnoses Vu A. Ngo, DO Department of Family Medicine and Dermatology Choctaw Nation Health Services Authority Learning Objectives Introduction to dermoscopy
More informationMECHANISMS OF HUMAN DISEASE: LABORATORY SESSION PATHOLOGY OF THE SKIN LAB. Friday, February 12, :30 am 11:00 am
MECHANISMS OF HUMAN DISEASE: LABORATORY SESSION PATHOLOGY OF THE SKIN LAB Friday, February 12, 2012 9:30 am 11:00 am FACULTY COPY GOALS: Describe the basic clinical and morphologic features of various
More informationBenign and malignant epithelial lesions: Seborrheic keratosis: A common benign pigmented epidermal tumor occur in middle-aged or older persons more
Benign and malignant epithelial lesions: Seborrheic keratosis: A common benign pigmented epidermal tumor occur in middle-aged or older persons more common on the trunk; but extremities, head and neck are
More informationCorporate Medical Policy
Corporate Medical Policy Gene Expression Profiling for Cutaneous Melanoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gene_expression_profiling_for_cutaneous_melanoma 5/2018
More informationCollaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]
CS Tumor Size Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ] Note: the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the physician's
More informationClinical Pathological Conference. Malignant Melanoma of the Vulva
Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationMelanoma and Dermoscopy. Disclosure Statement: ABCDE's of melanoma. Co-President, Usatine Media
Melanoma and Dermoscopy Richard P. Usatine, MD, FAAFP Professor, Family and Community Medicine Professor, Dermatology and Cutaneous Surgery Medical Director, University Skin Clinic University of Texas
More informationDisclosures. I have no conflicts of interest to disclose
Disclosures I have no conflicts of interest to disclose Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco 2
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationDavid B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma
Common Medicolegal Situations: Misdiagnosis of Melanoma David B. Troxel, MD Medical Director, The Doctors Company, Napa, California Clinical Professor Emeritus, University of California at Berkeley Past
More informationSkin Cancers Emerging Trends and Treatment Approaches
Skin Cancers Emerging Trends and Treatment Approaches Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement Copyright 2017 by Sea
More informationMalignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received
More informationGeneral information about skin cancer
Skin Cancer General information about skin cancer Key points Skin cancer is a disease in which malignant (cancer) cells form in the tissues of the skin. There are different types of cancer that start in
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES OCULAR ONCOLOGY PERIOCULAR CUTANEOUS MALIGNANCY Site Group: Ocular Periocular Cutaneous Malignancies Prepared by: Harmeet S. Gill MD, FRCSC
More informationProposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL
Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL on behalf of Dr Louise Lansbury, Prof Fiona Bath-Hextall Nottingham Centre for Evidence Based
More informationMALIGNANT MELANOMA. Dr D. Tenea Department of Dermatology University of Pretoria
MALIGNANT MELANOMA Dr D. Tenea Department of Dermatology University of Pretoria BACKGROUND History MM. of the skin is a malignant neoplasm of the epidermal melanocytes The incidence rates show considerable
More informationPoor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment
Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment Makenzie L. Hawkins, MSPH 1 Matthew J. Rioth, MD 1,2 Megan M. Eguchi, MPH 1 Myles Cockburn, Phd
More informationMelanoma. Walt Mudie - Block 5
Melanoma Walt Mudie - Block 5 Melanoma Graphic Warning Medical names: cutaneous melanoma (melanoma of skin), intraocular melanoma (melanoma of eye) Affects mainly skin, can also affect eye, vagina or anus
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationCURRENT ISSUES IN TRANSPLANT DERMATOLOGY
CURRENT ISSUES IN TRANSPLANT DERMATOLOGY NO CONFLICTS OF INTEREST TO DISCLOSE SOLID ORGAN TRANSPLANTATION: 2015 As of April 10, 2015.. 123,319 patients waiting for an organ transplant 2,557 performed this
More informationDisclosures. Melanoma and Non melanoma Skin Cancer: What You Need to Know. I have no conflicts of interest to disclose
Disclosures Melanoma and Non melanoma Skin Cancer: What You Need to Know I have no conflicts of interest to disclose Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department
More informationTalking to Your Clients About Skin Cancer. Objectives 9/9/2017. Amanda Friedrichs, MD, FAAD AMTA National Conference September 14, 2017
Talking to Your Clients About Skin Cancer Amanda Friedrichs, MD, FAAD AMTA National Conference September 14, 2017 Objectives Provide general information about skin cancer and how skin cancers commonly
More informationRegression 2/3/18. Histologically regression is characterized: melanosis fibrosis combination of both. Distribution: partial or focal!
Regression Margaret Oliviero MSN, ARNP Harold S. Rabinovitz MD Histologically regression is characterized: melanosis fibrosis combination of both Distribution: partial or focal! Dermatoscopic terminology
More informationSection 1: Personal information
A survey on the use of ultrasound examination of the regional lymph nodes in the follow up of patients with high-risk cutaneous squamous cells carcinomas (SCCs). Note: In the definition of cutaneous squamous
More informationأملس عضلي غرن = Leiomyosarcoma. Leiomyosarcoma 1 / 5
Leiomyosarcoma 1 / 5 EPIDEMIOLOGY Exact incidence is unknown, but older studies suggest that leiomyosarcomas comprise approximately 3 percent of soft-tissue sarcomas. Superficial leiomyosarcoma occurs
More informationMELANOMA. Some people are more likely to get a m Melanoma than others:
MELANOMA This leaflet has been written to help you understand more about Melanoma. It tells you what is it, what causes it, what can be done about it, how it can be prevented, and where you can find out
More informationMalignant Melanoma Introduction increasing incidence increasing mortality skin >50% normal skin pigmented lesion
1 Malignant Melanoma Introduction Melanoma is a malignant tumor of melanocytes, cells that are derived from the neural crest. There is an increasing incidence of melanoma, as well as an increasing mortality,
More informationWhen Do I Consider Myself Cured?
The Melanoma Patient Symposium - Science to Survivorship When Do I Consider Myself Cured? 26 September 2009 Jeffrey E. Gershenwald, MD, FACS Professor of Surgery, Dept. of Surgical Oncology Professor,
More informationSkin Cancer A Personal Approach. Dr Matthew Strack Dunedin New Zealand
Skin Cancer A Personal Approach Dr Matthew Strack Dunedin New Zealand Outline Dermoscopy Instruments and setup Photochemosurgery Clinical Aim: Leave with 2-3 ideas JLE Benign Junctional Nevus Management
More informationOverview of Cutaneous Lymphomas: Diagnosis and Staging. Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology
Overview of Cutaneous Lymphomas: Diagnosis and Staging Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology Definition of Lymphoma A cancer or malignancy that comes from
More informationEpidemiology. Objectives 8/28/2017
Case based Discussion of Head and Neck Melanoma: Review of Epidemiology, Risk Factors, Identification, Treatments and Prevention Jacqueline M. Doucette MS FNP-C Objectives Define and identify melanoma
More informationBasal cell carcinoma 5/28/2011
Goal of this Presentation A practical approach to the diagnosis of cutaneous carcinomas and their mimics Thaddeus Mully, MD University of California San Francisco To review common non-melanoma skin cancers
More informationAJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases
More informationLPN2008 l Volume 4, Number 4
36 LPN2008 l Volume 4, Number 4 2.0 CONTACT HOURS PAMELA R. JAKUBEK, RN, CWOCN, MSN Wound, Ostomy, Continence Clinical Nurse Specialist ROBIN NEWMILLER, RN, BA Clinical Nurse for Mohs Clinical Suite Fox
More informationA PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL
A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of
More informationI have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee
I have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee Some thoughts Is this skin cancer? How common is this? How likely is this in this patient? What happens next if it s something
More informationYou Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018
You Are Going to Cut How Much Skin? Locoregional Surgical Treatment Justin Rivard MD, MSc, FRCSC September 21, 2018 Presenter Disclosure Faculty/Speaker: Justin Rivard Relationships with financial sponsors:
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationNAACCR Hospital Registry Webinar Series
NAACCR Hospital Registry Webinar Series October 4, 2007 Abstracting Melanoma Cancer Incidence and Treatment Data Image source: commons.wikimedia.org/wiki/image.melanoma.jpg Sites include Melanoma Skin
More informationReview of Cutaneous Malignancies
Review of Cutaneous Malignancies Tanya Nino, MD Department of Dermatology Did You Know? More than 3.5 million skin cancers are diagnosed in the US annually Melanoma incidence rates have been increasing
More informationPathology. Skin Tumor. Bayan N. Mohammad 15/10/2015. Mohammad al-orjani. Page 0 of 23
#7 35 Pathology Skin Tumor Bayan N. Mohammad 15/10/2015 Mohammad al-orjani Page 0 of 23 بسم هللا الرحمن الرحيم GREETINGS This lecture is about skin tumors, all the slides are included and every slide will
More informationMelanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective
Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures
More informationContrast with Australian Guidelines A/Pr Pascale Guitera,
Contrast with Australian Guidelines A/Pr Pascale Guitera, Dermatologist, Sydney University NO CONFLICT OF INTEREST Sydney Melanoma Diagnostic Centre, RPAH 2011 2008 225 pages 16 pages http://www.cancer.org.au/file/healthprofessionals/clinica
More informationSKIN HISTOLOGY AND FUNCTION
SKIN HISTOLOGY AND FUNCTION THREE LAYERS : EPIDERMIS BASEMENT MEMBRANE DERMIS EPIDERMIS : COMPOSED OF KERATINOCYTES NO MATRIX DEEP BASAL LAYER MITOTICALLY ACTIVE SPINOUS LAYER MATURE HYALIN HORNY LAYER
More informationMultiple Primary Melanoma in a Thai Male: A Case Report
Case Report Multiple Primary Melanoma in a Thai Male: A Case Report J Med Assoc Thai 2014; 97 (Suppl. 2): S234-S238 Full text. e-journal: http://www.jmatonline.com Kittisak Payapvipapong MD*, Pinyapat
More informationCancer Reporting for Dermatologists. Florida Department of Health Florida Cancer Data System. March 9, Agenda
Cancer Reporting for Dermatologists Florida Department of Health Florida Cancer Data System March 9, 2011 Agenda Welcome Introductions Cancer Reporting in Florida BETA Participation Expectations Review
More informationDirectly Coded Summary Stage Melanoma
Directly Coded Summary Stage Melanoma National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention and Control, National Program of Cancer Registries Directly Coded
More informationDescribe the functions of the vertebrate integumentary system. Discuss the structure of the skin and how it relates to function.
Chapter 5 Describe the functions of the vertebrate integumentary system. Discuss the structure of the skin and how it relates to function. Explain the basis for different skin colors. Describe the structure
More information